Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (121-130 of 192) with videos related to

Pageof 20
Sort By:
The Journal of Antimicrobial Chemotherapy|June 26, 2025
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona CohortRoberta Gagliardini, Sara De Benedittis, Alessandro Tavelli, et al.
Open Forum Infectious Diseases|March 18, 2026
Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine LandscapeValeria Bono, Camilla Tincati, Matteo Augello, et al.
HIV Research & Clinical Practice|March 5, 2020
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day <i>vs</i> triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluationValentina Di Cristo, Fulvio Adorni, Renato Maserati, et al.
Plos One|October 24, 2017
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling studyMikaela Smit, Rachel Cassidy, Alessandro Cozzi-Lepri, et al.
Health Policy (Amsterdam, Netherlands)|October 15, 2021
Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic: Did age make the difference?Caterina Trevisan, Claudio Pedone, Stefania Maggi, et al.
International Journal of STD & AIDS|January 8, 2025
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohortAndrea Antinori, Giulia Marchetti, Vincenzo Esposito, et al.
Antiviral Research|July 9, 2019
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort studyBarbara Rossetti, Gianmaria Baldin, Gaetana Sterrantino, et al.
International Journal of Antimicrobial Agents|May 20, 2024
Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 studyAmedeo De Nicolò, Alice Palermiti, Stefania Dispinseri, et al.
AIDS (London, England)|November 28, 2023
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocationCamilla Tincati, Valeria Bono, Elvira Stefania Cannizzo, et al.
The Journal of Antimicrobial Chemotherapy|February 24, 2026
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomesLaura Pezzati, Federico Conti, William Gennari, et al.
Pageof 20

Showing results (121-130 of 192) with videos related to

Sort By:
Pageof 20
The Journal of Antimicrobial Chemotherapy|June 26, 2025
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona CohortRoberta Gagliardini, Sara De Benedittis, Alessandro Tavelli, et al.
Open Forum Infectious Diseases|March 18, 2026
Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine LandscapeValeria Bono, Camilla Tincati, Matteo Augello, et al.
HIV Research & Clinical Practice|March 5, 2020
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day <i>vs</i> triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluationValentina Di Cristo, Fulvio Adorni, Renato Maserati, et al.
Plos One|October 24, 2017
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling studyMikaela Smit, Rachel Cassidy, Alessandro Cozzi-Lepri, et al.
Health Policy (Amsterdam, Netherlands)|October 15, 2021
Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic: Did age make the difference?Caterina Trevisan, Claudio Pedone, Stefania Maggi, et al.
International Journal of STD & AIDS|January 8, 2025
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohortAndrea Antinori, Giulia Marchetti, Vincenzo Esposito, et al.
Antiviral Research|July 9, 2019
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort studyBarbara Rossetti, Gianmaria Baldin, Gaetana Sterrantino, et al.
International Journal of Antimicrobial Agents|May 20, 2024
Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 studyAmedeo De Nicolò, Alice Palermiti, Stefania Dispinseri, et al.
AIDS (London, England)|November 28, 2023
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocationCamilla Tincati, Valeria Bono, Elvira Stefania Cannizzo, et al.
The Journal of Antimicrobial Chemotherapy|February 24, 2026
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomesLaura Pezzati, Federico Conti, William Gennari, et al.
Pageof 20